|
Year
|
Title
|
Authors
|
Publication
|
|
2021
|
Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: A time-trend analysis.
|
Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M
|
Blood Cancer J 11(4):82
|
|
2021
|
National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide.
|
Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang X-Y, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales M-A, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J
|
J Clin Oncol
|
|
2021
|
Hematopoietic cell transplant outcomes among Medicaid and privately insured patients with sickle cell disease
|
Mupfudze TG, Meyer C, Preussler JM, Mau L-W, Bolon Y-T, Steinert P, Arnold SD, Saber W, Krishnamurti L
|
Transplant Cell Ther
|
|
2021
|
Return to work among young adult survivors of allogeneic hematopoietic cell transplantation in the United States.
|
Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau L-W, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, M Battiwalla, Schoemans H, Hamilton B, Buchbinder D, Phelan R, Shaw B
|
Transplant Cell Ther
|
|
2021
|
COVID-19 and Hematopoietic Cell Transplant Center-specific survival analysis: Can we adjust for the impact of the pandemic? Recommendations of the COVID-19 Taskforce of the 2020 CIBMTR Center Outcomes Forum.
|
Wingard JR, Ahn KW, Dandoy C, Perales M-A, Wood WA, Logan B, Riches M, Rizzo JD
|
Transplant Cell Ther
|
|
2021
|
Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation.
|
Duncan C, St. Martin A, Pérez WS, Steinert P, Zhang M-J, Chirnomas D, Hoang CJ, Loberiza FR Jr, Saber W
|
Pediatr Blood Cancer
|
|
2021
|
Genetics of HLA peptide presentation, and impact on outcomes in HLA-matched allo-HCT.
|
Story CM, Wang T, Bhatt VR, Battiwalla M, Badawy SM, Kamoun M, Gragert L, Brown V, Baxter-Lowe LA, Marsh SG, Gadalla SM, Schetelig J, Myilineos J, Miklos D, Waller E, Kuxhausen M, Spellman S, Lee S, Paczesny S, Lansford JL, Vincent BG, Riches ML, Armistead PM
|
Transplant Cell Ther
|
|
2021
|
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
|
Percival M-E, Wang H-L, Zhang M-J, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM
|
Bone Marrow Transplant
|
|
2021
|
HLA haploidentical versus matched unrelated donor transplants with post-transplant cyclophosphamide based prophylaxis.
|
Gooptu M, Romee R, St Martin A, Arora M, Al Malki MM, Antin JH, Bredeson CN, Brunstein C, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece I, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M
|
Blood
|
|
2021
|
Impact of previously unrecognized hla mismatches using ultrahigh resolution typing in unrelated donor hematopoietic cell transplantation.
|
Mayor NP, Wang T, Lee SJ, Kuxhausen M, Vierra-Green C, Barker DJ, Auletta J, Bhatt VR, Gadalla SM, Gragert L, Inamoto Y, Morris GP, Paczesny S, Reshef R, Ringdén O, Shaw BE, Shaw P, Spellman SR, Marsh SGE
|
J Clin Oncol
|
|
2021
|
A qualitative analysis of state Medicaid coverage benefits for allogeneic hematopoietic cell transplantation (alloHCT) for patients with sickle cell disease (SCD).
|
Mupfudze TG, Preussler JM, Sees JA, SanCartier M, Arnold SD, Devine S
|
Transplant Cell Ther 27(4):345-351
|
|
2021
|
Salvage second transplantation in relapsed multiple myeloma.
|
Dhakal B, D'Souza A, Kleman A, Chhabra S, Mohan M, Hari P
|
Leukemia 35(4):1214-1217
|
|
2021
|
Serious adverse events in related donors: A report from the Related Donor Safe Study.
|
Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE, Jacobsohn DA, Litzow MR, Magalhaes-Silverman M, Selby GB, Vusirikala M, Horowitz MM, Switzer GE, Confer DL, Shaw BE, Pulsipher MA
|
Transplant Cell Ther 27(4):352.e1-352.e5
|
|
2021
|
Epigenetic aging and hematopoietic cell transplantation in patients with severe aplastic anemia.
|
Alsaggaf R, Katta S, Wang T, Hicks BD, Zhu B, Spellman SR, Lee SJ, Horvath S, Gadalla SM
|
Transplant Cell Ther 27(4):313.e1-313.e8
|
|
2021
|
Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee.
|
Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ
|
Bone Marrow Transplant 56(4):786-797
|
|
2021
|
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: Analysis from CALGB 10403 and the CIBMTR.
|
Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang M-J, Bo-Subait K, Wang H-L, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, De Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D
|
Leukemia
|
|
2021
|
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
|
Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer R-L, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A
|
Leukemia
|
|
2021
|
Breaking the age barrier: Physicians’ perceptions on candidacy for allogeneic hematopoietic cell transplantation in older adults.
|
Asmita MIshra, Jaime M Preussler, Bhatt VR, Bredeson C, Chhabra S, D'Souza A, Dahi PB, Danaher Hacker E, Gowda L, Hashmi SK, Howard DS, Jakubowski A, Jayani R, Koll T, Lin R, Olin RL, Popat UR, Rodriguez C, Rosko A, Sabloff M, Sorror ML, Sung AD, Ustun C, Wood WA, Burns L, Artz A
|
Transplant Cell Ther
|
|
2021
|
The effect of donor graft cryopreservation on allogeneic hematopoietic cell transplantation outcomes: A Center for International Blood and Marrow Transplant Research analysis. Implications during the COVID-19 pandemic.
|
Hsu JW, Farhadfar N, Murthy HS, Logan BR, Bo-Subait S, Frey N, Goldstein SC, Horowitz MM, Lazarus HM, Schwanke JD, Shah NN, Spellman SR, Switzer GE, Devine SM, Shaw BE, Wingard JR
|
Transplant Cell Ther
|
|
2021
|
Shorter interdonation interval contributes to lower cell counts in subsequent stem cell donations.
|
Panch SR, Logan B, Sees JA, Bo-Subait S, Savani B, Shah NN, Hsu JW, Switzer G, Lazarus HM, Anderlini P, Hematti P, Confer D, Pulsipher MA, Shaw BE, Stroncek DF
|
Transplant Cell Ther
|
|
2021
|
Post-Transplant Cyclophosphamide (PTCy) is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis.
|
Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea SO, Dandoy CE, Angel Diaz M, Fuchs EJ, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri K, Krem M, Lazarus HM, Liu H, Ljungman P, Maziarz RT, Mulroney C, Nathan S, Nishihori T, Page KM, Perales M-A, Taplitz RA, Romee R, Riches M
|
Blood
|
|
2021
|
Changes in hematopoietic cell transplantation practices in response to COVID-19: A survey from the Worldwide Network for Blood & Marrow Transplantation.
|
Worel N, Shaw BE, Aljurf M, Koh M, Seber A, Weisdorf D, Schwartz J, Galeano S, Kodera Y, Eldridge PW, Hashmi S, Atsuta Y, Szer J, Saber W, Niederwieser D, Greinix HT
|
Transplant Cell Ther 27(3):270.e1-270.e6
|
|
2021
|
Application and evaluation of survivorship care guides for hematopoietic cell transplantation recipients.
|
Preussler JM, Payton TJ, Moore HK, Denzen EM, McCann M, Mau L-W
|
Transplant Cell Ther 27(3):266.e1-266.e7
|
|
2021
|
How old is too old for a transplant?
|
Weisdorf D
|
Best Pract Res Clin Haematol 34(1):101243
|
|
2021
|
Bortezomib-based induction is associated with superior outcomes in light chain amyloidosis patients treated with autologous hematopoietic cell transplantation regardless of plasma cell burden.
|
Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A
|
Transplant Cell Ther 27(3):264.e1-264.e7
|
|
2021
|
Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations regarding essential medications required to establish an early stage hematopoietic cell transplantation program.
|
El Fakih R, Greinix H, Koh M, Shaw B, Mohty M, Al Nahedh M, Saber W, Kharfan-Dabaja MA, Perales M-A, Savani BN, Majhail NS, Passweg JR, Sureda A, Ahmed SO, Gluckman E, Riches M, El-Jawahri A, Rondelli D, Srivastava A, Faulkner L, Atsuta Y, Ballen KK, Rasheed W, Okamoto S, Seber A, Chao N, Kröger N, Kodera Y, Szer J, Hashmi SK, Horowitz MM, Weisdorf D, Niederwieser D, Aljurf M
|
Transplant Cell Ther 27(3):267.e1-267.e5
|
|
2021
|
A unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models.
|
Martens MJ, Logan BR
|
Stat Med 40(5):1121-1132
|
|
2021
|
Impact of pretransplantation renal dysfunction on outcomes after allogeneic hematopoietic cell transplantation
|
Farhadfar N, Dias A, Wang T, Fretham C, Chhabra S, Murthy HS, Broglie L, D'Souza A, Gadalla SM, Gale RP, Hashmi S, Al-Homsi AS, Hildebrandt GC, Hematti P, Rizzieri D, Chee L, Lazarus HM, Bredeson C, Jaimes EA, Beitinjaneh A, Bashey A, Prestidge T, Krem MM, Marks DI, Benoit S, Yared JA, Nishihori T, Olsson RF, Freytes CO, Stadtmauer E, Savani BN, Sorror ML, Ganguly S, Wingard JR, Pasquini M
|
Biol Blood Marrow Transplant
|
|
2021
|
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial
|
Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez H, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME
|
Transplant Cell Ther
|
|
2021
|
Alternative donor transplantation for myelodysplastic syndromes: Haploidentical relative and matched unrelated donors.
|
Grunwald MR, Zhang M-J, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M
|
Blood Adv 5(4):975-983
|
|
2021
|
A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
|
Qayed M, Ahn KW, Kitko CL, Johnson MH, Shah NN, Dvorak C, Mellgren K, Friend BD, Verneris MR, Leung W, Toporski J, Levine J, Chewning J, Wayne A, Kapoor U, Triplett B, Schultz KR, Yanik GA, Eapen M
|
Blood 137(7):983-993
|
|
2021
|
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.
|
Hong S, Brazauskas R, Hebert KM, Ganguly S, Abdel-Azim H, Diaz MA, Beattie S, Ciurea SO, Szwajcer D, Badawy SM, Gratwohl AA, LeMaistre C, Aljurf MDSM, Olsson RF, Bhatt NS, Farhadfar N, Yared JA, Yoshimi A, Seo S, Gergis U, Beitinjaneh AM, Sharma A, Lazarus H, Law J, Ulrickson M, Hashem H, Schoemans H, Cerny J, Rizzieri D, Savani BN, Kamble RT, Shaw BE, Khera N, Wood WA, Hashmi S, Hahn T, Lee SJ, Rizzo JD, Majhail NS, Saber W
|
Cancer 127(4):609-618
|
|
2021
|
Is there still a role for allogeneic transplantation in the management of lymphoma?
|
Shah NN, Hamadani M
|
J Clin Oncol 39(5):487-498
|
|
2021
|
Building a fit for purpose clinical trials infrastructure to accelerate the assessment of novel hematopoietic cell transplantation strategies and cellular immunotherapies.
|
Devine SM, Horowitz MM
|
J Clin Oncol 39(5):534-544
|
|
2021
|
Hematopoietic Cell Transplantation Predictions for the Year 2023
|
Fahadfar N, Burns LJ, Mupfudze T, Shaw BE, Bollard CM, Devine SM, Horowitz MM, Jones RJ, Murthy HS, Wingard JR, Lee SJ
|
Biol Blood Marrow Transplant 27(2):183.e1-183.e7
|
|
2021
|
Likelihood of proceeding to allogeneic hematopoietic cell transplantation in the United States after search activation in the National Registry: Impact of patient age, disease, and search prognosis.
|
Dehn J, Chitphakdithai P, Shaw BE, McDonald AA, Devine SM, Burns LJ, Spellman S
|
Biol Blood Marrow Transplant 27(2):184.e1-184.e13
|
|
2021
|
Specific class I HLA supertypes but not HLA zygosity or expression are associated with outcomes following HLA-matched allogeneic hematopoietic cell transplant: HLA supertypes impact allogeneic HCT outcomes.
|
Camacho-Bydume C, Wang T, Sees JA, Fernandez-Viña M, Abid MB, Askar M, Beitinjaneh A, Brown V, Castillo P, Chhabra S, Gadalla SM, Hsu JM, Kamoun M, Lazaryan A, Nishihori T, Page K, Schetelig J, Fleischhauer K, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Hsu KC
|
Biol Blood Marrow Transplant 27(2):142.e1-142.e11
|
|
2021
|
Statistical methods for time-dependent variables in hematopoietic cell transplantation studies.
|
Kim S, Logan B, Riches M, Chen M, Ahn KW
|
Biol Blood Marrow Transplant 27(2):125-132
|
|
2021
|
Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: A CIBMTR analysis.
|
Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann SN, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR
|
Bone Marrow Transplant 56(2):522
|
|
2021
|
Broad spectrum antibiotics and risk of graft-versus-host disease in pediatric patients transplanted for acute leukemia: association of carbapenem use with risk of acute GVHD.
|
Elgarten CW, Li Y, Getz KD, Hemmer M, Huang Y-SV, Hall M, Wang T, Kitko CL, Jagasia MH, Nishihori T, Murthy HS, Hashem H, Cairo MS, Sharma A, Hashmi SK, Askar M, Beitinjaneh A, Kelly MS, Auletta JJ, Badawy SM, Mavers M, Aplenc R, MacMillan ML, Spellman SR, Arora M, Fisher BT
|
Transplant Cell Ther 27(2):177.e1-177.e8
|
|
2021
|
Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: A CIBMTR analysis.
|
Bona K, Brazauskas R, He N, Lehmann L, Abdel-Azim H, Ahmed IA, Al-Homsi AS, Aljurf M, Arnold SD, Badawy SM, Battiwalla M, Beattie S, Bhatt NS, Dalal J, Dandoy CE, Diaz MA, Frangoul HA, Freytes CO, Ganguly S, George B, Gomez-Almaguer D, Hahn T, Kamble RT, Knight JM, LeMaistre CF, Law J, Lazarus HM, Majhail NS, Olsson RF, Preussler J, Savani BN, Schears R, Seo S, Sharma A, Srivastava A, Steinberg A, Szwajcer D, Wirk B, Yoshimi A, Khera N, Wood WA, Hashmi S, Duncan CN, Saber W
|
Blood 137(4):556-568
|
|
2021
|
Acute GVHD diagnosis and adjudication in a multicenter trial: A report from the BMT CTN 1202 Biorepository Study.
|
Reshef R, Saber W, Bolaños-Meade J, Chen G, Chen Y-B, Ho VT, Ponce DM, Nakamura R, Martens MJ, Hansen JA, Levine JE
|
J Clin Oncol
|
|
2021
|
Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee.
|
Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ
|
Transplant Cell Ther
|
|
2021
|
Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.
|
Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, Laetsch TW, Wiener L, Gardner RA, Nussenblatt V, Hill JA, Curran KJ, Olson TS, Annesley C, Wang H-W, Khan J, Pasquini MC, Duncan C, Grupp S, Pulsipher MA, Shah NN
|
Nat Rev Clin Oncol
|
|
2021
|
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: The BMT CTN 1101 trial.
|
Fuchs EJ, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, Devine S, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein CG
|
Blood 137(3):420-428
|
|
2021
|
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.
|
Sharma A, Bhatt NS, St. Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales M-A, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL
|
Lancet Haematol
|
|
2021
|
Haplotype motif-based models for KIR-genotype informed selection of hematopoietic cell donors fail to predict outcome of patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
|
Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede LC, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee SJ, Kröger N, Hsu K, Schmidt AH, Yakoub-Agha I, Robin M
|
Front Immunol 11:584520
|
|
2021
|
Phase II trial of costimulation blockade with
abatacept for prevention of acute GVHD.
|
Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS
|
J Clin Oncol
|
|
2021
|
Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post–unrelated HCT.
|
Wang Y, Zhou W, Wang J, Karaesmen E, Tang H, McCarthy PL, Pasquini MC, Wang Y, McReynolds LJ, Katki HA, Machiela MJ, Yeager M, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, Wang T, Kuxhausen M, Chanock SJ, Lee SJ, Clay-Gilmour AI, Hahn TE, Gadalla SM, Sucheston-Campbell LE
|
Blood Adv 5(1):66-70
|
|
2021
|
Corrigendum to "Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation" [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885].
|
Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang M-J, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari P, Hamadani M
|
Transplant Cell Ther
|
|
2021
|
Myeloablative conditioning for allogeneic transplantation results in superior disease-free survival for acute myelogenous leukemia and myelodysplastic syndromes with low/intermediate but not high disease risk index: A Center for International Blood and Marrow Transplant Research Study.
|
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn J-Y, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier BM, Litzow M, Kebriaei P, Saber W, Weisdorf D
|
Biol Blood Marrow Transplant 27(1):68.e1-68.e9
|
|
2021
|
Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy.
|
Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M
|
Biol Blood Marrow Transplant 27(1):55.e1-55.e7
|
|
2021
|
Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction.
|
Shah NN, Schneiderman J, Kuruvilla D, Bhojwani D, Fry TJ, Martin PL, Schultz KR, Silverman LB, Whitlock JA, Wood B, Vainshtein I, Adams A, Confer D, Pulsipher MA, Chaudhury S, Wayne AS
|
Pediatr Blood Cancer 68(1):e28574
|
|
2021
|
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
|
Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Paquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, San Miguel J, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B
|
Leukemia 35(1):18-30
|
|
2021
|
Impact of reduced-intensity conditioning regimens on outcomes in diffuse large B cell lymphoma undergoing allogeneic transplantation.
|
Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M
|
Biol Blood Marrow Transplant 27(1):58-66
|
|
2021
|
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
|
Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A
|
Cancer 127(1):82-92
|
|
2021
|
Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant.
|
Dhakal B, Wang T, Kuxhausen M, Zhu F, Taylor C, Spellman SR, Verneris MR, Hsu K, Fleischhauer K, Lee SJ, Bolon Y-T, Carlson K-S, Nazha A, Saber W
|
Leuk Lymphoma 62(1):229-233
|
